Search Results - "Attaya, Victoria"

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer by Keenan, Tanya E., Guerriero, Jennifer L., Barroso-Sousa, Romualdo, Li, Tianyu, O’Meara, Tess, Giobbie-Hurder, Anita, Tayob, Nabihah, Hu, Jiani, Severgnini, Mariano, Agudo, Judith, Vaz-Luis, Ines, Anderson, Leilani, Attaya, Victoria, Park, Jihye, Conway, Jake, He, Meng Xiao, Reardon, Brendan, Shannon, Erin, Wulf, Gerburg, Spring, Laura M., Jeselsohn, Rinath, Krop, Ian, Lin, Nancy U., Partridge, Ann, Winer, Eric P., Mittendorf, Elizabeth A., Liu, David, Van Allen, Eliezer M., Tolaney, Sara M.

“…Immune checkpoint inhibitors (ICIs) have minimal therapeutic effect in hormone receptor-positive (HR+ ) breast cancer. We present final overall survival (OS)…”
Get full text

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer by Waks, Adrienne G, Keenan, Tanya E, Li, Tianyu, Tayob, Nabihah, Wulf, Gerburg M, Richardson, Edward T, Attaya, Victoria, Anderson, Leilani, Mittendorf, Elizabeth A, Overmoyer, Beth, Winer, Eric P, Krop, Ian E, Agudo, Judith, Van Allen, Eliezer M, Tolaney, Sara M

“…BackgroundPreclinical and clinical data support potential synergy between anti-HER2 therapy plus immune checkpoint blockade. The safety and tolerability of…”
Get full text

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer by Mayer, Erica L, Ren, Yue, Wagle, Nikhil, Mahtani, Reshma, Ma, Cynthia, DeMichele, Angela, Cristofanilli, Massimo, Meisel, Jane, Miller, Kathy D, Abdou, Yara, Riley, Elizabeth C, Qamar, Rubina, Sharma, Priyanka, Reid, Sonya, Sinclair, Natalie, Faggen, Meredith, Block, Caroline C, Ko, Naomi, Partridge, Ann H, Chen, Wendy Y, DeMeo, Michelle, Attaya, Victoria, Okpoebo, Amanda, Alberti, Jillian, Liu, Yuan, Gauthier, Eric, Burstein, Harold J, Regan, Meredith M, Tolaney, Sara M

“…Cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6is) are an important component of treatment for hormone receptor-positive/human epidermal growth factor…”
Get full text

Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer by Bardia, Aditya, Sun, Sheng, Thimmiah, Nayana, Coates, James T., Wu, Bogang, Abelman, Rachel O., Spring, Laura, Moy, Beverly, Ryan, Phoebe, Melkonyan, Mark N., Partridge, Ann, Juric, Dejan, Peppercorn, Jeffrey, Parsons, Heather, Wander, Seth A., Attaya, Victoria, Lormil, Brenda, Shellock, Maria, Nagayama, Aiko, Bossuyt, Veerle, Isakoff, Steven J., Tolaney, Sara M., Ellisen, Leif W.

“…Abstract Purpose: The antibody–drug conjugate (ADC) sacituzumab govitecan (SG) comprises the topoisomerase 1 (TOP1) inhibitor (TOP1i) SN-38, coupled to a…”
Get full text

Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies by Jovanović, Bojana, Church, Sarah E, Gorman, Kara M, North, Khrystyna, Richardson, 3rd, Edward T, DiLullo, Molly, Attaya, Victoria, Kasparian, Julie, Mohammed-Abreu, Ayesha, Kirkner, Gregory, Hughes, Melissa E, Lin, Nancy U, Mittendorf, Elizabeth A, Schnitt, Stuart J, Tolaney, Sara M, Goel, Shom

“…Triple-negative breast cancer (TNBC) is a heterogeneous disease that carries the poorest prognosis of all breast cancers. Although novel TNBC therapies in…”
Get full text

Abstract GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC) by Barroso-Sousa, Romualdo, Li, Tianyu, Reddy, Sangeetha, Emens, Leisha A., Overmoyer, Beth, Lange, Paulina, Dilullo, Molly K, Attaya, Victoria, Kimmel, Jeffrey, Winer, Eric P., Mittendorf, Elizabeth A., Tayob, Nabihah, Tolaney, Sara M.

“…Abstract Background: While high tumor mutational burden (TMB-H) has been used as a tissue-agnostic biomarker for approval of immune checkpoint inhibitors…”
Get full text

Abstract P2-14-18: A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer by Garrido-Castro, Ana C, Graham, Noah, Bi, Kevin, Park, Jihye, Fu, Jingxin, Keenan, Tanya, Richardson, Edward Thomas, Pastorello, Ricardo, Lange, Paulina, Attaya, Victoria, Wesolowski, Robert, Sinclair, Natalie, Lucas, Zarah, Lo, Steve, Tung, Nadine, Faggen, Meredith, Kaufman, Peter A, Block, Caroline C, Briccetti, Fred, Toke, Madhavi, Chen, Wendy, Wucherpfennig, Kai, Marx, Sascha, Tian, Ye, Agudo, Judith, Guerriero, Jennifer L, Schnitt, Stuart, Lin, Nancy U, Winer, Eric P, Mittendorf, Elizabeth A, Tayob, Nabihah, Van Allen, Eliezer, Tolaney, Sara M

“…Abstract Background: Platinum agents induce DNA crosslinking and cause accumulation of genotoxic stress, which leads to immune activation via IFN-γ signaling,…”
Get full text

Abstract PO4-12-11: Patient (pt) time burden with IV vs subcutaneous (SC) administration of trastuzumab/pertuzumab (HP): A time and motion (T+M) substudy of a single arm phase II trial of adjuvant endocrine therapy plus HP for stage I HER2+ breast cancer by Waks, Adrienne, Graham, Noah, Chen, Emily, Frey, Anna Mae, Attaya, Victoria, Abbass, Ibrahim, Fung, Anita, Sussell, Jesse, Cortazar, Patricia, Harvey, Caroline, Almeida, Kenneth, Leth, Denise, Chen, Wendy, Leone, Jose, Schumer, Susan, Tayob, Nabihah, Tolaney, Sara

“…Abstract Background: The time required for in-clinic drug administration may have a substantial detrimental impact on breast cancer patients’ quality of life…”
Get full text

Abstract PO2-27-12: Genomic determinants of benefit to nivolumab (NIVO) plus low dose ipilimumab (IPI) among patients (pts) with hypermutated HER2-negative metastatic breast cancer (MBC): results of NIMBUS trial by Barroso-Sousa, Romualdo, Chinsky, Tyler, Li, Tianyu, Reddy, Sangeetha, Emens, Leisha, Overmoyer, Beth, AlDubayan, Saud, Chu, Hoyin, Lange, Paulina, Kasparian, Julie, Basta, Ameer, DiLullo, Molly, Attaya, Victoria, Hughes, Melissa, Lin, Nancy, Tayob, Nabihah, Jeselsohn, Rinath, Mittendorf, Elizabeth, Tolaney, Sara

“…Abstract Background: Genomic determinants of benefit to immune checkpoint inhibitors (ICI) among pts with MBC and high tumor mutational burden (TMB-H) are…”
Get full text

Abstract CT188: A phase Ib study of sapacitabine (sapa) and olaparib (ola) in patients (pts) with BRCA1/2- mutated ( BRCA1/2 m) metastatic breast cancer (MBC) by Lynce, Filipa, Graham, Noah, Kochupurakkal, Bose S., Nguyen, Huy, Poorvu, Philip D., Attaya, Victoria, Davis, Raechel, Garg, Kavita, Lim, Lee P., Li, Mark, Paweletz, Cloud P., Tayob, Nabihah, Shapiro, Geoffrey I., Tolaney, Sara M.

“…Abstract Background: PARP inhibitors (PARPi) are superior to chemotherapy in pts with BRCA1/2m MBC, with median PFS (mPFS) of 7 months with single-agent ola…”
Get full text

Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients by Bardia, Aditya, Sun, Sheng, Thimmiah, Nayana, Coates, James T, Wu, Bogang, Abelman, Rachel O, Spring, Laura, Moy, Beverly, Ryan, Phoebe, Melkonyan, Mark N, Partridge, Ann, Juric, Dejan, Peppercorn, Jeffrey, Parsons, Heather, Wander, Seth A, Attaya, Victoria, Lormil, Brenda, Shellock, Maria, Nagayama, Aiko, Bossuyt, Veerle, Isakoff, Steven J, Tolaney, Sara M, Ellisen, Leif W

“…The Antibody-Drug Conjugate (ADC) Sacituzumab govitecan (SG) comprises the topoisomerase 1 (TOP1) inhibitor SN-38, coupled to a monoclonal antibody targeting…”
Get full text

Abstract PO2-20-01: The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+ Metastatic Breast Cancer (TBCRC 062) by Parsons, Heather, Ruddy, Kathryn, Morganti, Stefania, Smith, Karen, Attaya, Victoria, Kallfelz, Eliza, DeMeo, Michelle, LaScala, Jamie, Mertz, Shirley, Pollastro, Teri, Spears, Patricia, Brufsky, Adam, Dang, Chau, Dent, Susan, Elkhanany, Ahmed, Gwin, WIlliam, O'Sullivan, Ciara, Miller, Kathy, Nunnery, Sara, Walsh, Elaine, Storniolo, Anna Maria, Tolaney, Sara, Tayob, Nabihah, Wolff, Antonio, Winer, Eric, Rimawi, Mothaffar, Krop, Ian, Lin, Nancy

“…Abstract BACKGROUND: Anti-HER2 therapies have transformed the trajectory for patients with HER2-positive (HER2+) MBC. A subset of patients with HER2+ MBC do…”
Get full text

Abstract PD7-03: Translational Breast Cancer Research Consortium Trial 022: Neratinib and Trastuzumab-Emtansine for HER2+ Breast Cancer Brain Metastases (BCBM) by Freedman, Rachel, Ren, Siyang, Tayob, Nabihah, Gelman, Rebecca, Smith, Karen L., Davis, Raechel, Pereslete, Alyssa, Attaya, Victoria, Cotter, Christine, Chen, Wendy Y., Santa-Maria, Cesar Augusto, Van Poznak, Catherine, Moy, Beverly, Brufsky, Adam M., Melisko, Michelle, O’Sullivan, Ciara C., Ashai, Nadia, Rauf, Yasmeen, Nangia, Julie, Trapani, Dario, Savoie, Jennifer, Burns, Robyn, Wolff, Antonio C., Winer, Eric, Rimawi, Mothaffar, Krop, Ian, Lin, Nancy U.

“…Abstract PURPOSE: Treatment options for patients (pts) with HER2+ BCBM remain limited. We previously reported that neratinib monotherapy is associated with a…”
Get full text

Abstract GS3-06: GS3-06 Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer by Mayer, Erica L., Ren, Yue, Wagle, Nikhil, Mahtani, Reshma, Ma, Cynthia, DeMichele, Angela, Cristofanilli, Massimo, Meisel, Jane, Miller, Kathy D., Jolly, Trevor, Riley, Elizabeth, Qamar, Rubina, Sharma, Priyanka, Reid, Sonya, Sinclair, Natalie, Faggen, Meredith, Block, Caroline, Ko, Naomi, Partridge, Ann, Chen, Wendy Y., DeMeo, Michelle K., Attaya, Victoria, Okpoebo, Amanda, Liu, Yuan, Gauthier, Eric, Burstein, Harold, Regan, Meredith, Tolaney, Sara

“…Abstract Background CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) have a well-established role in the management of hormone…”
Get full text

Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit by Barroso-Sousa, Romualdo, Forman, Juliet, Collier, Katharine, Weber, Zachary T, Jammihal, Tejas R, Kao, Katrina Z, Richardson, 3rd, Edward T, Keenan, Tanya, Cohen, Ofir, Manos, Michael P, Brennick, Ryan C, Ott, Patrick A, Hodi, F Stephen, Dillon, Deborah A, Attaya, Victoria, O'Meara, Tess, Lin, Nancy U, Van Allen, Eliezer M, Rodig, Scott, Winer, Eric P, Mittendorf, Elizabeth A, Wu, Catherine J, Wagle, Nikhil, Stover, Daniel G, Shukla, Sachet A, Tolaney, Sara M

“…In metastatic triple-negative breast cancer (mTNBC), consistent biomarkers of immune checkpoint inhibitor (ICI) therapy benefit remain elusive. We evaluated…”
Get more information

Abstract 2638: Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triple-negative breast cancer (TNBC): Translational investigation by Bardia, Aditya, Coates, James T., Spring, Laura, Sun, Sheng, Juric, Dejan, Thimmiah, Nayana, Niemierko, Andrzej, Ryan, Phoebe, Partridge, Ann, Peppercorn, Jeffrey, Parsons, Heather, Wander, Seth, Pierce, Kelsey, Attaya, Victoria, Fitzgerald, Donna, Lormil, Brenda, Shellock, Maria, Nagayama, Aiko, Bossuyt, Veerle, Moy, Bev, Tolaney, Sara, Ellisen, Leif

“…Abstract Background: Sacituzumab Govitecan (SG), the first antibody-drug conjugate approved for metastatic TNBC (mTNBC), is comprised of SN-38 (active…”
Get full text